Heavy Light Chain in Chronic Lymphocytic Leukemia
Launched by BNAI ZION MEDICAL CENTER · Feb 25, 2015
Trial Information
Current as of May 30, 2025
Unknown status
Keywords
ClinConnect Summary
Analysis of immunoglobulin heavy/light chain pairs In chronic lymphocytic leukemia
Introduction and Background:
Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in the western world. Median age at diagnosis is 72 years, and the male to female ratio is 2:1. The disease is characterized by an accumulation of monoclonal mature B-cells which co-express the T-cell antigen CD5, B-cell surface antigens CD19, CD20, and CD23(1) and either kappa or lambda immunoglobulin light chains restriction (2). Diagnosis is established based on the IWCLL criteria published by Hallek at al...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • New diagnosed patients with CLL (untreated)
- Exclusion Criteria:
- • Not treated with immunoglobulin Not treated with steroids
About Bnai Zion Medical Center
Bnai Zion Medical Center is a leading healthcare institution dedicated to advancing medical research and patient care. Located in Haifa, Israel, the center is recognized for its commitment to innovative clinical trials that aim to enhance treatment outcomes across various medical fields. With a multidisciplinary team of experts and state-of-the-art facilities, Bnai Zion Medical Center fosters a collaborative environment that supports the development of cutting-edge therapies and contributes to the global medical community. The center's focus on ethical research practices and patient safety underscores its mission to improve health and well-being for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Haifa, , Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials